MRK.DE - MERCK Kommanditgesellschaft auf Aktien

XETRA - XETRA Delayed price. Currency in EUR
82.76
-1.64 (-1.94%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous close84.40
Open83.86
Bid0.00 x 6700
Ask0.00 x 11200
Day's range82.26 - 84.54
52-week range74.54 - 112.65
Volume405,212
Avg. volume594,722
Market cap35.931B
Beta0.94
PE ratio (TTM)14.89
EPS (TTM)5.56
Earnings date9 Aug 2018
Forward dividend & yield1.25 (1.48%)
Ex-dividend date2018-04-30
1y target estN/A
  • Merck KGaA Sees Profit Falling on Liquid Crystals Struggle
    Bloomberg Videolast month

    Merck KGaA Sees Profit Falling on Liquid Crystals Struggle

    May.15 -- Marcus Kuhnert, chief financial officer at Merck KGaA, discusses profitability in the company's Liquid Crystals business, their pricing strategy and his outlook for reorganizing the business. He speaks on "Bloomberg Markets: European Open."

  • Merck KGaA CEO Happy With Portfolio, Celebrating 350th Year of Existence
    Bloomberg Video2 months ago

    Merck KGaA CEO Happy With Portfolio, Celebrating 350th Year of Existence

    May.03 -- Stefan Oschmann, chief executive officer at Merck KGaA, discusses the company's history and outlook. He speaks with Matt Miller and Guy Johnson on “Bloomberg Markets: European Open.”

  • Merck KGaA's lung cancer drugs show promise in early-stage trials
    Business Insider UKlast month

    Merck KGaA's lung cancer drugs show promise in early-stage trials

    Germany's Merck KGaA said two of its experimental oncology drugs showed early signs of promise in certain lung cancer patients, potentially helping the company's efforts to find drug-industry partners to share further development costs. The family-controlled company on Wednesday released some initial data from early- and mid-stage trials that will be presented in more detail at the annual conference of the American Society of Clinical Oncology (ASCO) in Chicago in early June. A bifunctional fusion protein known as M7824, which combines two immunotherapy mechanism, led to tumour shrinkage in 40.7 percent of patients in a small study group suffering from non-small cell lung cancer (NSCLC).

  • Merck KGaA's lung cancer drugs show promise in early-stage trials
    Business Insider UKlast month

    Merck KGaA's lung cancer drugs show promise in early-stage trials

    Germany's Merck KGaA said two of its experimental oncology drugs showed early signs of promise in certain lung cancer patients, potentially helping the company's efforts to find drug-industry partners to share further development costs. The family-controlled company on Wednesday released some initial data from early- and mid-stage trials that will be presented in more detail at the annual conference of the American Society of Clinical Oncology (ASCO) in Chicago in early June. A bifunctional fusion protein known as M7824, which combines two immunotherapy mechanism, led to tumour shrinkage in 40.7 percent of patients in a small study group suffering from non-small cell lung cancer (NSCLC).

  • Merck KGaA (MKGAF) Q1 Earnings and Revenues Decline Y/Y
    Zackslast month

    Merck KGaA (MKGAF) Q1 Earnings and Revenues Decline Y/Y

    Merck KGaA (MKGAF) reports dismal first-quarter results with earnings declining year over year. Revenues fall due to continued negative currency movement.

  • Merck KGaA Sees Profit Falling on Liquid Crystals Struggle
    Bloomberglast month

    Merck KGaA Sees Profit Falling on Liquid Crystals Struggle

    Marcus Kuhnert, chief financial officer at Merck KGaA, discusses profitability in the company's Liquid Crystals business, their pricing strategy and his outlook for reorganizing the business. He speaks ...

  • The Wall Street Journallast month

    [$$] Merck KGaA's Sales Fall

    Merck KGaA reported a 4.4% drop in first-quarter sales, hit by currency fluctuations.

  • What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?
    Zackslast month

    What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?

    Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.

  • Reuters2 months ago

    Merck KGaA family says unreservedly behind the pharma unit

    The family behind Germany's Merck KGaA (MRCG.DE) said it was fully committed to the diversified group's pharmaceuticals unit, even if cancer immunotherapy hopeful avelumab does not achieve blockbuster sales. If avelumab doesn't become a blockbuster there are enough highly interesting products in our pipeline," said family representative Frank Stangenberg-Haverkamp, speaking at an event marking the group's 350-year anniversary at its Darmstadt, Germany headquarters.

  • Bloomberg2 months ago

    Merck KGaA CEO Happy With Portfolio, Celebrating 350th Year of Existence

    Stefan Oschmann, chief executive officer at Merck KGaA, discusses the company's history and outlook. He speaks with Matt Miller and Guy Johnson on “Bloomberg Markets: European Open.” (Source: Bloomberg)...

  • Barrons.com2 months ago

    Health-Care Earnings: Merck, Pfizer Disappoint With Q1 Revenue

    Biotech has seen better days, and it doesn't look much better as you move up the food chain to big pharma either, as both Merck (MRK) and Pfizer (PFE) are falling after the two disappointed with first-quarter ...

  • Merck vs. Pfizer: Which Stock is Better Before Q1 Earnings?
    Zacks2 months ago

    Merck vs. Pfizer: Which Stock is Better Before Q1 Earnings?

    With both Merck and Pfizer are scheduled to report on May 1, this may be a good time to figure out which of these is a better stock.

  • Reuters2 months ago

    P&G to buy German Merck's consumer health unit for $4.2 billion

    The maker of Pampers diapers and Gillette razors said the deal would help it expand its portfolio of consumer healthcare products which includes Vicks cold relief. The Merck unit includes vitamin brands Femibion and Neurobion. The deal follows GlaxoSmithKline agreeing to buy Novartis out of their consumer healthcare joint venture for $13 billion after dropping its pursuit of Pfizer's consumer unit.

  • EQS Group2 months ago

    Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

    Merck KGaA23.04.2018 / 12:40 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Notification of Major Holdings1. Details of issuerMerck KGaAFrankfurter Str. 25064293 DarmstadtGermany2. Reason for notificationXAcquisition/disposal of shares with voting rights Acquisition/disposal of instruments Change of breakdown of voting rights Other reason:3. ...

  • Germany's Merck seeks partners for cancer and immune system drugs
    Reuters2 months ago

    Germany's Merck seeks partners for cancer and immune system drugs

    Merck KGaA will seek development partners for experimental treatments including tepotinib as the German company looks to licensing deals to help fund clinical trials, according to its head of drug R&D. Merck has a promising drug pipeline for the first time in several years. It is looking to take a collaborative approach, as an expected decline in operating profit this year forces it to find new ways to finance pharmaceutical development.

  • Reuters - UK Focus2 months ago

    P&G's vitamin boost could signal more to come

    LONDON/CHICAGO, April 20 (Reuters) - Procter & Gamble (Swiss: PG-USD.SW - news) 's $4.2 billion deal for Merck (LSE: 0O14.L - news) 's vitamin and supplements business demonstrates that major consumer companies remain hungry for health-related products. The fragmented nature of the sector and its appeal to younger consumers makes further M&A activity a likely prospect even after a spate of recent acquisitions. The U.S.-based maker of Tide (Oslo: TIDE.OL - news) detergent and Gillette razors announced its plan on Thursday to buy Merck brands such as Seven Seas vitamins.

  • The Wall Street Journal2 months ago

    Corrections & Amplifications

    Corrections & Amplifications for the edition of April 20, 2018.

  • Reuters2 months ago

    P&G to buy German Merck's consumer health unit for $4.2 billion

    The maker of Pampers diapers and Gillette razors said the deal would help it expand its portfolio of consumer healthcare products which includes Vicks cold relief. The Merck unit includes vitamin brands Femibion and Neurobion. The deal follows GlaxoSmithKline agreeing to buy Novartis out of their consumer healthcare joint venture for $13 billion after dropping its pursuit of Pfizer's consumer unit.

  • P&G to buy German Merck's consumer health unit for $4.2 billion
    Reuters2 months ago

    P&G to buy German Merck's consumer health unit for $4.2 billion

    The maker of Pampers diapers and Gillette razors said the deal would help it expand its portfolio of consumer healthcare products which includes Vicks cold relief. The Merck unit includes vitamin brands Femibion and Neurobion. The deal follows GlaxoSmithKline agreeing to buy Novartis out of their consumer healthcare joint venture for $13 billion after dropping its pursuit of Pfizer's consumer unit.

  • The Wall Street Journal2 months ago

    [$$] P&G Needs a Workout, Not Vitamins

    European dietary supplements won’t cure what ails Procter & Gamble. The consumer products maker should focus on fixing its core business to resume growth.

  • Reuters - UK Focus2 months ago

    LIVE MARKETS-Closing snapshot: flat, but results spark movers

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger to share your thoughts on market ...

  • Reuters - UK Focus2 months ago

    LIVE MARKETS-Discounters' bite could hurt Tesco, Morrisons

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger to share your thoughts on market ...

  • Reuters - UK Focus2 months ago

    LIVE MARKETS-Defensives have further to go

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger to share your thoughts on market ...

  • Reuters - UK Focus2 months ago

    LIVE MARKETS-Rigging European volatility "very unlikely", French watchdog finds

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger to share your thoughts on market ...

  • Reuters - UK Focus2 months ago

    LIVE MARKETS-Plastic - not so popular

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger to share your thoughts on market ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes